

Prophylaxis against covid-19: living systematic review a

BMJ, The

373, n949

DOI: [10.1136/bmj.n949](https://doi.org/10.1136/bmj.n949)

Citation Report

#	ARTICLE	IF	CITATIONS
1	Drug treatments for covid-19: living systematic review and network meta-analysis. BMJ, The, 2020, 370, m2980.	3.0	592
2	A living WHO guideline on drugs to prevent covid-19. BMJ, The, 2021, 372, n526.	3.0	73
3	Covid-19: India's crisis is everyone's crisis. BMJ, The, 0, , n1152.	3.0	0
5	What we learned in the past year in managing our COVID-19 patients in intensive care units?. World Journal of Critical Care Medicine, 2021, 10, 81-101.	0.8	5
7	WHO COVID-19 therapeutic guidelines – Authors' reply. Lancet, The, 2021, 398, 118.	6.3	2
8	Triangle of cytokine storm, central nervous system involvement, and viral infection in COVID-19: the role of sFasL and neuropilin-1. Reviews in the Neurosciences, 2022, 33, 147-160.	1.4	22
9	Early COVID-19 therapy with azithromycin plus nitazoxanide, ivermectin or hydroxychloroquine in outpatient settings significantly improved COVID-19 outcomes compared to known outcomes in untreated patients. New Microbes and New Infections, 2021, 43, 100915.	0.8	20
10	Efficacy and safety of hydroxychloroquine as pre-and post-exposure prophylaxis and treatment of COVID-19: A systematic review and meta-analysis of blinded, placebo-controlled, randomized clinical trials.. The Lancet Regional Health Americas, 2021, 2, 100062.	1.5	33
11	Efficacy and safety of current medications for treating severe and non-severe COVID-19 patients: an updated network meta-analysis of randomized placebo-controlled trials. Aging, 2021, 13, 21866-21902.	1.4	17
12	Extreme immunotherapy: emergency immunology to defeat pandemics. Molecular Medicine, 2021, 27, 112.	1.9	0
14	Pharmacological interventions to prevent Covid-19 disease: A rapid review. Reviews in Medical Virology, 2021, , e2299.	3.9	7
15	Antibody and cellular therapies for treatment of covid-19: a living systematic review and network meta-analysis. BMJ, The, 2021, 374, n2231.	3.0	59
16	Ivermectin for Prophylaxis and Treatment of COVID-19: A Systematic Review and Meta-Analysis. Diagnostics, 2021, 11, 1645.	1.3	22
17	An update of anti-viral treatment of COVID-19. Turkish Journal of Medical Sciences, 2021, 51, 3372-3390.	0.4	55
18	Translating Evidence to Optimize Patient Care Using GRADE. Journal of Allergy and Clinical Immunology: in Practice, 2021, 9, 4221-4230.	2.0	30
20	Self-medication practices to prevent or manage COVID-19: A systematic review. PLoS ONE, 2021, 16, e0259317.	1.1	63
21	Post-exposure Lopinavir-Ritonavir Prophylaxis versus Surveillance for Individuals Exposed to SARS-CoV-2: The COPEP Pragmatic Open-Label, Cluster Randomized Trial. EClinicalMedicine, 2021, 42, 101188.	3.2	5
22	Ivermectin. Clinical Nurse Specialist, 2022, 36, 16-19.	0.3	1

#	ARTICLE	IF	CITATIONS
23	Ocular and Systemic Complications of COVID-19: Impact on Patients and Healthcare. <i>Clinical Ophthalmology</i> , 2022, Volume 16, 1-13.	0.9	16
24	Non-immune Prophylaxis Against COVID-19 by Targeting Tolerance for Angiotensin II-Triggered SARS-CoV-2 Pathogenesis. <i>Frontiers in Medicine</i> , 2021, 8, 776903.	1.2	1
25	The Effect of Circulating Zinc, Selenium, Copper and Vitamin K1 on COVID-19 Outcomes: A Mendelian Randomization Study. <i>Nutrients</i> , 2022, 14, 233.	1.7	21
27	An update on drugs with therapeutic potential for SARS-CoV-2 (COVID-19) treatment. <i>Drug Resistance Updates</i> , 2021, 59, 100794.	6.5	175
28	Ofelein i mi Vlapinâ€™Volume II: Immunity Following Infection or mRNA Vaccination, Drug Therapies and Non-Pharmacological Management at Post-Two Years SARS-CoV-2 Pandemic. <i>Medicina (Lithuania)</i> , 2022, 58, 309.	0.8	4
29	Maoto, a traditional herbal medicine, for post-exposure prophylaxis for Japanese healthcare workers exposed to COVID-19: A single center study. <i>Journal of Infection and Chemotherapy</i> , 2022, 28, 907-911.	0.8	4
30	Ivermectin and the Integrity of Healthcare Evidence During COVID-19. <i>Frontiers in Public Health</i> , 2022, 10, 788972.	1.3	6
31	Coronavirus Infection-Associated Cell Death Signaling and Potential Therapeutic Targets. <i>Molecules</i> , 2021, 26, 7459.	1.7	30
32	Antirheumatic Drugs against COVID-19 from the Perspective of Rheumatologists. <i>Pharmaceuticals</i> , 2021, 14, 1256.	1.7	10
33	Rural Medical Care and COVID-19. <i>Journal of the Japanese Association of Rural Medicine</i> , 2022, 70, 594-603.	0.0	0
34	Drug safety of frequently used drugs and substances for self-medication in COVID-19. <i>Therapeutic Advances in Drug Safety</i> , 2022, 13, 204209862210941.	1.0	7
35	Ayurvedic formulations: Potential COVID-19 therapeutics?. <i>Phytomedicine Plus</i> , 2022, 2, 100286.	0.9	7
36	Artificial intelligence in COVID-19 evidence syntheses was underutilized, but impactful: a methodological study. <i>Journal of Clinical Epidemiology</i> , 2022, , .	2.4	11
37	Single Dose of Ivermectin is not Useful in Patients with Hematological Disorders and COVID-19 Illness: A Phase II B Open Labelled Randomized Controlled Trial. <i>Indian Journal of Hematology and Blood Transfusion</i> , 2022, 38, 615-622.	0.3	4
38	Lessons from SARSâ€™CoVâ€™2 and its variants (Review). <i>Molecular Medicine Reports</i> , 2022, 26, .	1.1	5
39	Changes in dispensing of medicines proposed for re-purposing in the first year of the COVID-19 pandemic in Australia. <i>PLoS ONE</i> , 2022, 17, e0269482.	1.1	5
40	Safety and Non-Inferiority Evaluation of Two Immunization Schedules with an Inactivated SARS-CoV-2 Vaccine in Adults: A Randomized Clinical Trial. <i>Vaccines</i> , 2022, 10, 1082.	2.1	8
41	Prevention of venous thromboembolic events in patients with lower leg immobilization after trauma: Systematic review and network meta-analysis with meta-epidemiological approach. <i>PLoS Medicine</i> , 2022, 19, e1004059.	3.9	4

#	ARTICLE	IF	CITATIONS
42	Treatment for acute respiratory distress syndrome in adults: a narrative review of phase 2 and 3 trials. <i>Expert Opinion on Emerging Drugs</i> , 2022, 27, 187-209.	1.0	5
43	Characteristics of Living Systematic Review for COVID-19. <i>Clinical Epidemiology</i> , 0, Volume 14, 925-935.	1.5	2
45	Improving the adherence to COVID-19 preventive measures in the community: Evidence brief for policy. <i>Frontiers in Public Health</i> , 0, 10, .	1.3	2
46	Medications for the treatment of pulmonary arterial hypertension: a systematic review and network meta-analysis. <i>European Respiratory Review</i> , 2022, 31, 220036.	3.0	9
47	Systematic review and meta-analysis of randomized trials of hydroxychloroquine for the prevention of COVID-19. <i>European Journal of Epidemiology</i> , 2022, 37, 789-796.	2.5	14
48	Perceptions of COVID-19 symptoms, prevention, and treatment strategies among people in seven Arab countries: A cross-sectional study. <i>Journal of Infection and Public Health</i> , 2022, 15, 1108-1117.	1.9	2
49	The scenario of self-medication practices during the covid-19 pandemic; a systematic review. <i>Annals of Medicine and Surgery</i> , 2022, 82, .	0.5	13
50	COVID-19 incidence, severity, medication use, and vaccination among dentists: survey during the second wave in Brazil. <i>Journal of Applied Oral Science</i> , 0, 30, .	0.7	2
51	Failed clinical trials on COVID-19 acute respiratory distress syndrome in hospitalized patients: common oversights and streamlining the development of clinically effective therapeutics. <i>Expert Opinion on Investigational Drugs</i> , 2022, 31, 995-1015.	1.9	4
52	Potential limitations in systematic review studies assessing the effect of the main intervention for treatment/therapy of COVID-19 patients: An overview. <i>Frontiers in Medicine</i> , 0, 9, .	1.2	4
53	Consistency of covid-19 trial preprints with published reports and impact for decision making: retrospective review. , 2022, 1, e000309.		19
54	Long COVID in Patients with Rheumatologic Disease: A Single Center Observational Study. <i>Indian Journal of Rheumatology</i> , 2023, 18, 212-217.	0.2	3
55	PROPHYLACTIC USE OF ALLOPATHIC, COMPLEMENTARY & ALTERNATIVE MEDICINE (CAM) FOR COVID-19: A CROSS SECTIONAL SURVEY AMONG MEDICAL POST-GRADUATES OF TERTIARY CARE TEACHING HOSPITALS, GUJARAT. , 2022, , 6-8.		0
56	Model exploration for discovering COVID-19 targeted traditional Chinese medicine. <i>Heliyon</i> , 2022, 8, e12333.	1.4	0
57	The Impact of Serum Levels of Vitamin D3 and Its Metabolites on the Prognosis and Disease Severity of COVID-19. <i>Nutrients</i> , 2022, 14, 5329.	1.7	4
59	FXR inhibition may protect from SARS-CoV-2 infection by reducing ACE2. <i>Nature</i> , 2023, 615, 134-142.	13.7	131
60	The Comparison of Clinical Epidemiology of Hospitalized Patients with COVID-19 during the Third and Fourth Waves of the Pandemic in Gorgan. <i>Canadian Journal of Infectious Diseases and Medical Microbiology</i> , 2022, 2022, 1-6.	0.7	0
62	Results of a systematic review and meta-analysis of early studies on ivermectin in SARS-CoV-2 infection. <i>GeroScience</i> , 2023, 45, 2179-2193.	2.1	1

#	ARTICLE	IF	CITATIONS
63	Histamine-2 Receptor Antagonists and Proton Pump Inhibitors Are Associated With Reduced Risk of SARS-CoV-2 Infection Without Comorbidities Including Diabetes, Hypertension, and Dyslipidemia: A Propensity Score-Matched Nationwide Cohort Study. <i>Journal of Korean Medical Science</i> , 2023, 38, .	1.1	0
64	Mechanisms of gastrointestinal barrier dysfunction in COVID-19 patients. <i>World Journal of Gastroenterology</i> , 0, 29, 2283-2293.	1.4	3
65	UDCA, a novel strategy for preventing SARS-CoV-2 infection via FXR-mediated ACE2 downregulation. <i>Acta Biochimica Et Biophysica Sinica</i> , 2023, , .	0.9	0